Plain-English translation of NCT06225232 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether psilocybin—a naturally occurring psychedelic compound—when combined with counseling and therapy, can help people with cannabis use disorder quit or cut back on their use. Right now, there are very few effective treatments for cannabis dependence, so researchers want to see if this medication, given alongside professional support, could offer a new option.
Cannabis use disorder affects many people and can harm work, school, and relationships, but current treatments don't have high success rates. Early research suggests this medication may help with substance use problems, so this trial will explore whether it could work specifically for cannabis dependence.
You likely qualify if…
You likely don't qualify if…
Over 8 weeks, you would attend sessions at the study site where you'll receive two doses of the medication spaced apart, paired with therapy sessions focused on motivation and support for change. You'll have check-in appointments, complete questionnaires and rating scales, and be asked to arrange for someone to pick you up and stay with you overnight after each medication dose. The study also includes follow-up assessments to track your progress.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Canada